Free Republic 2nd Qtr 2024 Fundraising Target: $81,000 Receipts & Pledges to-date: $35,069
43%  
Woo hoo!! And we're now over 43%!! Thank you all very much!! God bless.

Keyword: prostatecancer

Brevity: Headers | « Text »
  • Component of keto diet plus immunotherapy may reduce prostate cancer (Ketones from keto diet or supplement)

    05/01/2024 9:06:05 PM PDT · by ConservativeMind · 3 replies
    Medical Xpress / University of Notre Dame / Cancer Research ^ | April 27, 2024 | Deanna Csomo Ferrell / Sean Murphy et al
    Adding a pre-ketone supplement—a component of a high-fat, low-carb ketogenic diet—to a type of cancer therapy in a laboratory setting was highly effective for treating prostate cancer, researchers found. Prostate cancer is resistant to a type of immunotherapy called immune checkpoint blockade (ICB) therapy. ICB therapy paves the way for our body's fighter cells, T cells, to kill the cancer. Murphy divided the models into different groups: immunotherapy alone, ketogenic diet alone, a pre-ketone supplement alone, the ketogenic diet with the immunotherapy, the supplement with the immunotherapy, and the control. While the immunotherapy alone had almost no effect on the...
  • Avoid Unnecessary Biopsies: New Urine-Based Test Detects High-Grade Prostate Cancer

    04/18/2024 12:56:39 PM PDT · by Red Badger · 19 replies
    SciTech Daily ^ | APRIL 18, 2024 | UNIVERSITY OF MICHIGAN
    New urine-based test looks at 18 genes and was specifically developed to pick out those cancers that need immediate treatment over the slow-growing type. Researchers at the University of Michigan Rogel Cancer Center have developed a new urine-based test that addresses a major problem in prostate cancer: how to separate the slow-growing form of the disease unlikely to cause harm from more aggressive cancer that needs immediate treatment. The test, called MyProstateScore2.0, or MPS2, looks at 18 different genes linked to high-grade prostate cancer. In multiple tests using urine and tissue samples from men with prostate cancer, it successfully identified...
  • Screening with a PSA test has a small impact on prostate cancer deaths but leads to overdiagnosis, finds study

    04/07/2024 11:43:00 AM PDT · by george76 · 30 replies
    Cancer Research UK ^ | APRIL 6, 2024 | Cancer Research UK
    The largest study to date investigating a single invitation to a PSA blood test to screen for prostate cancer has found it had a small impact on reducing deaths, but also led to overdiagnosis and missed early detection of some aggressive cancers. The CAP trial, published in the Journal of the American Medical Association (JAMA) and carried out by researchers from the universities of Bristol, Oxford and Cambridge, involved over 400,000 men aged 50-69. Just under half received a single invitation for a PSA test as part of the trial. After following up for 15 years, there was a small...
  • New research highlights combining prostate MRI with a blood test to avoid unnecessary prostate biopsies

    04/05/2024 10:06:37 PM PDT · by ConservativeMind · 13 replies
    MRI of the prostate, combined with a blood test, can help determine if a prostate lesion is clinically significant cancer, research suggests A new meta-analysis suggests doctors and patients can avoid unnecessary prostate biopsies by combining MRI of the prostate findings with prostate-specific antigen (PSA) density. To doctors, clinically significant prostate cancer (csPCa) is prostate cancer that has a high chance of threatening a patient's life. MRI of the prostate can provide some of this information. Still, a biopsy is traditionally needed to determine how aggressive the cancer cells look. This study tested a new approach: combining MRI-based prostate imaging...
  • DEFENSE SECRETARY AUSTIN’S PRESUMPTIVE REPLACEMENT WOKE DEEP-STATER, DR. KATHLEEN HICKS.

    02/12/2024 12:22:20 PM PST · by george76 · 22 replies
    Son of the new American Revolution ^ | 15 January 2024 | Bob Bishop
    Lloyd Austin underwent an invasive surgical procedure called a prostatectomy for his prostate cancer. He was readmitted to the ICU ward of Walter Reed National Military Medical Center seven days later, on January 1st, due to complications caused by a severe infection. It appears he was septic. He concealed his inability to carry out his duties from Biden, Congress, the Pentagon, and his Deputy Secretary, Dr. Kathleen Hicks. On January 4th, finally becoming aware of Austin’s hospitalization, security adviser Jake Sullivan notified Hicks, who was on vacation in Puerto Rico. Even though Biden continued to back Austin, Austin was already...
  • Increase in annual cardiorespiratory fitness by more than 3% linked to 35% lower prostate cancer risk

    02/03/2024 5:27:29 PM PST · by ConservativeMind · 3 replies
    An increase in annual cardiorespiratory fitness by 3% or more is linked to a 35% lower risk of developing, although not dying from, prostate cancer, suggests research. They wanted to find out if improvements in cardiorespiratory fitness over time might influence these risks, drawing on a national occupational health profile assessment database. The database collected information on physical activity, lifestyle, perceived health, measurement of body mass and height, and the results of at least two cardiorespiratory fitness tests, measured by peddling on a stationary cycle, for 57,652 men out of a total of 181,673. Annual cardiorespiratory fitness measurements were expressed...
  • Advanced Prostate Cancer Cases on the Rise After Years of Decline: What You Need to Know

    01/12/2024 8:25:26 AM PST · by george76 · 51 replies
    Epoch Times ^ | 1/12/2024 | Cara Michelle Miller
    U.S. Defense Secretary Lloyd Austin was recently diagnosed and is being treated for prostate cancer. He is one of the nearly 290,000 American men who will be diagnosed with the condition this year. Nearly all types of cancer have become less deadly over the last 30 years, with one notable exception: advanced-stage prostate cancer, according to a recent report from the American Cancer Society (ACS). “We have had more men diagnosed with more advanced prostate cancer over the last decade,” Dr. Sam S. Chang, the Chief Surgical Officer at the Vanderbilt Ingram Cancer Center, told The Epoch Times in an...
  • John Kirby: Biden Not Told Sec. Of Defense Austin Has Cancer Until Today

    01/09/2024 2:26:55 PM PST · by Macho MAGA Man · 26 replies
    The Gateway Pundit ^ | January 9, 2024 | Kristinn Taylor
    Joe Biden was not informed of the prostate cancer diagnosis of Secretary of Defense Lloyd Austin until today, National Security Council spokesman John Kirby told reporters at Tuesday’s White House press briefing. Kirby said Biden was told of Austin’s illness by White House Chief of Staff Jeff Zients in the morning. A press release earlier Tuesday by doctors treating Austin revealed his cancer diagnosis. ..... Snip..... Biden spoke by phone with Austin on Saturday, reported Politico’s Alex Ward, “Biden held a “cordial conversation” with Austin on Saturday night, per one of the U.S. officials. “The president has complete trust and...
  • A naturally-occurring molecule shows promise as effective first-line treatment for prostate cancer (Carnosine)

    Scientists wanted to investigate the anti-cancer properties of carnosine against cells derived from both primary and metastatic prostate cancer. Carnosine, which can be produced by the body and is also found in meat, has long been advocated for use as an antioxidant to facilitate healthy aging. There have been reports of carnosine being effective against the development of a number of different cancers but this is the first time it has been studied in relation to prostate cancer. The researchers found that carnosine stopped the cells from multiplying and at higher doses even killed cancer from both primary and metastatic...
  • Study sheds light on diabetes drug for prostate cancer (Metformin could help up to 60% of new cases)

    11/09/2023 10:04:27 PM PST · by ConservativeMind · 16 replies
    A study suggests metformin is a drug that could prevent the progression of prostate cancer, but only for tumors with low levels of NKX3.1, which are more likely to develop into aggressive cancers. The researchers found metformin restores cancer-fighting mitochondrial activity that is lost when NKX3.1 levels are low, prevents prostate cancer progression in mice, and is associated with better survival in patients with low-NKX3.1 tumors but not high-NKX3.1 tumors. Papachristodoulou found that when prostate cells are under oxidative stress (as happens during prostate cancer development), NKX3.1 moves into the cells' mitochrondria to reduce stress and protect the cells. If...
  • Docetaxel use associated with significant reduction in prostate cancer death in very poor prognostic group (70% reduction in deaths)

    11/04/2023 9:56:43 AM PDT · by ConservativeMind · 9 replies
    Men with high-grade prostate cancer and low prostate-specific antigen (PSA) levels have a poor prognosis. The question remains as to whether the chemotherapy drug docetaxel, which increases survival in metastatic prostate cancer, can improve the cure rate in these patients. In a new study by investigators from Brigham and Women's Hospital, a meta-analysis of five prospective randomized clinical trials (RCTs) found that adding docetaxel to standard-of-care (SOC) treatment was associated with a 70% reduction in death from prostate cancer-specific mortality (PCSM). Investigators performed a meta-analysis of the RCTs evaluating SOC treatment with radiotherapy and androgen deprivation therapy or with radical...
  • Drug combo ups progression-free survival for metastatic prostate cancer (talazoparib plus enzalutamide)

    06/11/2023 10:14:20 AM PDT · by ConservativeMind · 6 replies
    Medical Xpress / HealthDay / The Lancet ^ | June 8, 2023 | Elana Gotkine / Wassim Abida et al / Neeraj Agarwal et al
    For patients with metastatic castration-resistant prostate cancer (mCRPC), talazoparib plus enzalutamide results in improvement in radiographic progression-free survival (rPFS), according to a study. Neeraj Agarwal, M.D. and colleagues conducted a randomized phase 3 trial of talazoparib plus enzalutamide versus placebo plus enzalutamide as first-line therapy for men with asymptomatic or mildly symptomatic mCRPC receiving ongoing androgen deprivation therapy from 223 hospitals, cancer centers, and medical centers in 26 countries. Patients were prospectively assessed for homologous recombination repair gene alterations in tumor tissue and randomly assigned to once daily talazoparib or placebo (402 and 203 patients, respectively). The researchers found that...
  • Medical Mavens Discover Men and Women are Different: We’re well into the 21st century, but it’s breaking news when a doctor discovers what humans have known since time immemorial

    05/16/2023 7:59:03 AM PDT · by SeekAndFind · 9 replies
    American Thinker ^ | 05/16/2023 | Brian C. Joondeph, MD
    Medical journals are ranked by prestige, like universities and restaurants, based on criteria that might be more in the eye of the beholder than based on objective criteria. In the medical world, The Lancet and the New England Journal of Medicine are ranked number one and two, respectively, despite both having had to retract shoddy published COVID papers over “data integrity questions.”JAMA, or the Journal of the American Medical Association, is number five on the “best medicine journals” list. It would be reasonable to expect such journals to be publishing cutting-edge medical research papers rather than nonsense better suited for...
  • Transgender women are still at risk for prostate cancer

    04/30/2023 5:02:04 PM PDT · by aimhigh · 62 replies
    EurekaAlert ^ | 04/29/2023 | UNIVERSITY OF CALIFORNIA
    Transgender women keep their prostates even after gender-affirming surgery, but the extent to which they remain at risk of prostate cancer has been unclear. Now a first of its kind study led by UC San Francisco has estimated the risk at about 14 cases per 10,000 people. The study drew on 22 years of data from the Veterans Affairs Health System. Although the sample size was necessarily small, it is still the largest study of its kind. It publishes Saturday, April 29, 2023 in the Journal of the American Medical Association (JAMA) and is timed to the annual meeting of...
  • Transgender women are still at risk for prostate cancer

    05/01/2023 12:46:42 AM PDT · by glorgau · 49 replies
    MedicalXpress ^ | April 29, 2023 | University of California, San Francisco
    Transgender women keep their prostates even after gender-affirming surgery, but the extent to which they remain at risk of prostate cancer has been unclear. Now a first of its kind study led by UC San Francisco has estimated the risk at about 14 cases per 10,000 people. The study drew on 22 years of data from the Veterans Affairs Health System. Although the sample size was necessarily small, it is still the largest study of its kind. It publishes Saturday, April 29, 2023 in the Journal of the American Medical Association (JAMA) and is timed to the annual meeting of...
  • ENZAMET shows promise as prostate cancer treatment (Testosterone suppression plus enzalutamide 18% better than standard therapy with chemo)

    03/31/2023 6:50:32 PM PDT · by ConservativeMind · 8 replies
    Medical Xpress / University of Adelaide / The Lancet Oncology ^ | March 28, 2023 | Christopher J Sweeney et al
    A new drug combination for men with advanced prostate cancer has shown sustained increase in survival rates. The results from the clinical trial of ENZAMET, co-chaired by Professor Christopher Sweeney, have been published. For people with metastatic hormone-sensitive prostate cancer, the addition of an androgen receptor blocker with enzalutamide to standard therapy—suppression of testosterone, with or without chemotherapy—led to a 67 percent survival rate after five years. This compares to 57 percent of people who were alive after five years after receiving the standard best practice treatment. "The longer-term analysis showed that the benefit of adding enzalutamide was evident in...
  • Final Long-Term Results on Landmark Clinical Study Showing Modified Citrus Pectin Successfully Treats Biochemically Relapsed Prostate Cancer

    03/24/2023 5:18:16 PM PDT · by nickcarraway · 6 replies
    Better Health Publishing — Results from an 18 month phase II clinical trial on the benefits of dietary supplement modified citrus pectin in biochemically relapsed prostate cancer will be presented at the American Society for Clinical Oncology (ASCO) Genitourinary Cancer Symposium, Feb 16-18. Results showed that 18 months of treatment with researched modified citrus pectin (P-MCP) reduced prostate cancer progression, stabilized or decreased PSA, and slowed PSA doubling time (PSADT) without hormonal interference or side effects. These results highlight the clinically relevant benefits of P-MCP in prostate cancer Figure 1: Results from 18 month follow-up on P-MCP in BRPC presented...
  • Switch to plant-based diet could boost prostate cancer survival

    02/26/2023 10:42:02 AM PST · by ConservativeMind · 56 replies
    Following a healthy plant-based diet after a diagnosis of prostate cancer may help prevent the disease from progressing or recurring, a study suggests. Men who ate a diet rich in fruits, vegetables and whole grains had a 52% lower risk of cancer progressing and a 53% lower risk of recurrence, compared with men who had the lowest amounts of plants in their diet, the researchers found. A plant-based diet may have these benefits because fruits and vegetables contain antioxidants and anti-inflammatory components, as well as dietary fiber that improve glucose control and reduce inflammation, she explained. Also, this diet reduces...
  • New Study: How Ivermectin Kills Prostate Cancer Cells

    02/01/2023 4:39:09 PM PST · by cuz1961 · 46 replies
    Popular Rationalism ^ | Jan 31/2023 | James Lyons-Weiler
    : Integrated analysis reveals FOXA1 and Ku70/Ku80 as targets of ivermectin in prostate cancer The authors exposed various prostate cancer cells lines to Ivermectin and found that ivermectin binds to two proteins: FOXA1 and Ku70/Ku80. This leads to the inhibition of androgen receptor (AR), E2F1 expression, and DNA damage repair activity. The cells stopped dividing (G0/G1 cell cycle arrest), experience extensive DNA damage, and die.
  • Vladimir Putin 'DOES have Parkinson's and pancreatic cancer, leaked Kremlin spy documents claim'

    11/01/2022 2:29:46 PM PDT · by marcusmaximus · 65 replies
    Daily Mail ^ | 11/11/2022 | Jack Newman
    Vladimir Putin does have early stage Parkinson's disease and pancreatic cancer, leaked spy documents have alleged in the latest unverified claim about the tyrant's ill health. The Russian leader has been plagued with rumours about his illnesses for months and he has regularly appeared twitching and unsteady in public, sparking hope in Ukraine and the West the despot could soon relinquish power. Claims have been circulating among opposition figures, fuelled by his unexplained absences and his shaky public appearances, that he is battling serious health problems but they have always been rubbished by the Kremlin. -snip- 'Putin is regularly stuffed...